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Longitudinal SARS-CoV-2
seroconversion and
functional heterogeneity in a
pediatric dialysis unit
To the editor: Health care settings have a high risk of severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
spread and high seroconversion rates.1,2 Dialysis units are at
high risk for SARS-CoV-2 exposure because of frequent close
patient contact, a highly mobile patient population, and open
bay formats that limit social distancing.3
Little is known regarding longitudinal serologies in SARS-
CoV-2 and factors impacting neutralization.2 We have previ-
ously reported on 3 weeks of SARS-CoV-2 seroconversion in
health care workers and patients in a pediatric dialysis unit.2
This study describes 10 additional weeks of SARS-CoV-2
antibody measurements and neutralization potential.
Serum IgM and IgG levels were measured weekly on an
expanded cohort of participants for 10 additional weeks, for
13 weeks total (Supplementary Table S1). Five different SARS-
CoV-2 enzyme-linked immunosorbent assays and surrogate
virus neutralization assays were performed (Supplementary
Methods).
Fourteen patients on hemodialysis and 34 health care
workers participated in the study. By week 13, 12 of 34 health
care workers (35%) and 5 of 14 patients (38%) had SARS-
CoV-2 antibodies. During the first 6 weeks of the study, 4
patients and 10 health care workers seroconverted. Over the
remaining 4 weeks, 1 patient and 2 health care workers
seroconverted (Figure 1). Among those seroconverting in the
second portion of the study, all were asymptomatic except 1
nurse who developed anosmia after positive IgG test. The
majority of patients (80%) and health care workers (83%)
maintained seroconversion at week 13. Only 3 of 12 partici-
pants (25%) with polymerase chain reaction (PCR) test were
positive (Supplementary Figure S1).
Conceptually, antibodies that disrupt the receptor binding
domain (RBD) of the spike peptide binding to angiotensin II
converting enzyme (ACE2) will be neutralizing.4 Monoclonal
antibodies to the N-terminal domain (NTD) of spike are also
associated with neutralizing properties.4 Therefore, we
quantified NTD, RBD, and spike-specific antibodies.5 Addi-
tionally, we evaluated antibody status in SARS-CoV-2 PCR-
positive community volunteers. One-half (50%) of our health
care worker and patient cohort developed spike antibodies,
and 15% developed NTD antibodies. Of the PCR-positive
participants from the local community, 90% developed
spike antibodies and 47% developed NTD antibodies
(Supplementary Figure S1).
In our surrogate viral neutralization assay, we found a variable
range of neutralization rates from 0% to over 90%. We correlated
spike protein and NTD IgG optical density (OD) values to
quantitative neutralization (Supplementary Figure S2A–F). In
health care workers and the PCR-positive participants from the
local community, a strong correlation between NTD and
neutralization (R2 ¼ 0.879) existed. A weaker correlation between
spike and neutralization (R2 ¼ 0.410) existed (Supplementary
Figure S3). In our dialysis population, we did not find the same
correlation between NTD and neutralization (R2 ¼ 0.055)
(Supplementary Figure S2G and H). We confirmed these findings
with microneutralization studies in a subset of this cohort
(Supplementary Figure S4).
This study found rapid initial seroconversion followed by
slower ongoing seroconversion in individuals interacting in a
pediatric dialysis unit. To the best of our knowledge, this
represents the first report of variable NTD antibody devel-
opment after SARS-CoV-2 infection and correlation with
neutralization of RBD-ACE2 binding. The lack of correlation
in patients on dialysis between neutralization and serologies
offers insight into SARS-CoV-2 susceptibility and immune
dysfunction in patients on hemodialysis.6,7
Our antibody profiling and neutralization studies separate
our cohort into distinct groups. In the PCR-positive partici-
pants from the local community and health care workers, we
demonstrate a strong correlation between NTD and RBD-
ACE2 neutralization. It is unclear why some individuals
make spike antibodies to spike but not antibodies to the NTD.
Based on the in vitro assays, spike antibodies alone do not
prevent complexing of RBD to ACE2 receptors.4 Why only
certain individuals make high-quality RBD and NTD anti-
bodies that correlate to neutralization needs investigation.
Our finding of NTD conferring neutralization by preventing
RBD binding to ACE2 is novel. We postulate that NTD serves
as a surrogate marker for other mechanisms. Our pilot
microneutralization studies confirmed this finding. Eluci-
dating factors that lead to neutralizing antibodies will be
paramount for vaccine development and community
immunity.
Our patients on dialysis made NTD, RBD, and spike
antibodies, but they did not neutralize. Patients on dial-
ysis have adaptive immune deficiency, despite normal
antibody levels.8 We hypothesize that the uremic milieu
of end-stage renal disease leads to dysfunction much like
uremic platelet dysfunction (Supplementary Figure S5).9
This report offers potential insight into the poor out-
comes of patients on dialysis who have coronavirus dis-
ease 2019.3
A decreased rate of seroconversion over time occurred in
our participants despite children, some with documented
SARS-CoV-2, being grouped together during hemodialysis
sessions. A statewide “shelter in place” order and mandatory
mask requirement were implemented during the first 3 weeks
of this study and may be responsible for this decreased
seroconversion rate.2 We recognize limitations including that
the clinical consequences of serological neutralizing capability
are unknown. Seroconversion was generally sustained over
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several months in contrast to past studies, indicating decline
in seroconversion over time.10 Additionally participants with
no neutralization antibodies had mild symptoms or none at
all. Asymptomatic seroconversion without neutralization ca-
pabilities might result from a lower viral load, preexisting
resistance to disease conferred by T cells, or host-specific
factors.11
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Figure S1. Study flow diagram. Flow diagram depicting symptoms,
PCR testing results and laboratory testing for pediatric patients on
dialysis (n ¼ 14), community of SARS-CoV-2 PCR-positive control
participants (n ¼ 17), and health care workers (n ¼ 34).
Figure S2. Neutralizing antibodies against SARS-CoV-2 in patients
receiving dialysis, health care workers, and PCR-positive individuals
from the local community. Scatter plot illustrating distribution of (A)
spike IgG, (B) receptor-binding domain (RBD) IgG, and (C) N-terminal
domain (NTD) IgG to neutralization percentage in the community of
SARS-CoV-2 PCR-positive control participants (n ¼ 17) and health care
workers (n ¼ 21). Graph illustrating the relationship of the optical
density (OD) of (D) spike IgG, (E) RBD IgG, and (F) NTD IgG to per-
centage of neutralization in the community of SARS-CoV-2 PCR-positive
control participants (n ¼ 17) and health care workers (n ¼ 21). NTD IgG
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Figure 1 | Cumulative seroconversion (development of severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] IgM or IgG
antibodies) rates by week of study in patients receiving dialysis and health care workers. Individuals were considered seropositive based
on the study week in which they were first found to be seropositive for IgM, IgG, or both. The percentage of seroconverted pediatric patients
on dialysis (n ¼ 14) and health care workers (n ¼ 34) with cumulative N-terminal domain (NTD) antibody positivity and cumulative
neutralizing antibodies are shown as a proportion of the total seropositive rate in each week of the study.
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control participants from the local community and health care workers
(R2 ¼ 0.879) than was spike IgG antibody (R2 ¼ 0.410). Open elements
(diamonds, triangles, or circles) represent high titer samples, gray-
shaded elements represent positive but not high titer, and filled black
elements represent negative samples to correspond to A to C.
Threshold for IgG positivity denoted with horizontal dashed line. Linear
regression correlations were plotted with 95% confidence intervals
(dotted curves). (G) Scatter plot illustrating distribution of spike IgG
(diamonds), RBD IgG (triangles), and NTD IgG (circles) in pediatric pa-
tients on dialysis (n ¼ 10). Open elements represent positive samples
and closed represent negative samples. (H) Distribution of neutraliza-
tion for spike IgG-, RBD IgG-, and NTD IgG-positive samples.
Figure S3. Neutralizing antibodies against SARS-CoV-2 in health care
workers and PCR-positive individuals from the local community by IgG
antibody status. Relationship of spike IgG, receptor-binding domain
(RBD) IgG, and spike peptide N-terminal domain (NTD) IgG to per-
centage of neutralization. NTD IgG was associated with higher
neutralizing effect in the community of PCR-positive control participants
and health care workers with high OD (R2 ¼ 0.888) and spike IgG
antibody (R2 ¼ 0.834). No association was seen in those with low OD.
Threshold for IgG positivity denoted with horizontal dashed line. Linear
regression correlations were plotted with 95% confidence intervals
(dotted curves). Open elements (diamonds, triangles, or circles) repre-
sent positive samples and closed represent negative samples.
Figure S4. Microneutralization correlation to SARS-CoV-2 antibody
subsets. The community of SARS-CoV-2 PCR-positive control partici-
pants (n ¼ 17) illustrating the relationship among levels of spike IgG,
receptor-binding domain (RBD) IgG, and spike peptide N-terminal
domain (NTD) IgG to one-half maximal inhibitory concentration (IC50)
against live SARS-CoV-2.
Figure S5. Surrogate viral neutralization assay in different clinical
cohorts. SARS-CoV-2 binds to the ACE2 receptor for host cell inter-
nalization via the receptor-binding domain (RBD) of the spike protein.
Signal is produced by the absence of antibodies in the subject’s
serum enabling the binding of RBD to the ACE2 receptor. Signal is
absent when serum contains neutralization antibodies reflecting in-
hibition of binding. When serum contains robust spike IgG antibodies
and no neutralization antibodies, an increase in signal is demon-
strated potentially from spike IgG to RBD complexes binding to ACE2.
During uremia, we do not see the effect of neutralization antibodies
on RBD-ACE2 binding.
Table S1. Characteristics and cumulative SARS-CoV-2 seroconversion
for patients receiving dialysis and health care workers.
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Decline and loss of
anti–SARS-CoV-2 antibodies
in kidney transplant recipients
in the 6 months following
SARS-CoV-2 infection
To the editor: The dynamics of immune response to severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in
kidney transplant recipients (KTRs) remains largely unknown.
KTRs have been reported to develop serological responses to
SARS-CoV-2.1,2 However, information about the duration and
significance of antibody response in this immunocompromised
population is still critically lacking. We herein report anti–
SARS-CoV-2 IgG trajectory in a cohort of KTRs followed at
Necker Hospital (Paris, France) between 2 and 6 months after
symptomatic coronavirus disease 2019 (COVID-19) infection.
Forty-two patients (22 men [52.4%]; median age of 57.7
years; interquartile range [IQR]: 47.2–67.0), who developed
COVID-19 infection between March 14 andMay 2, 2020, were
included. COVID-19 was defined by typical clinical symptoms
associated to a positive SARS-CoV-2 polymerase chain reaction
test on nasopharyngeal swab. Sera were tested for the presence
6JJC and MCS are co-authors.
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